News

  1. B2B Trader

    We are looking for a B2B Trader. Join us and make your work count. We are a dynamic, fast growing, disruptive and mission-driven healthcare startup.

    Read more »
  2. Libtayo (cemiplimab): The only EU approved treatment for advanced CSCC

    New skin cancer medicine now approved in the EU for adults with metastatic or locally advanced cutaneous squamous cell carcinoma.

    EU approval OK hand gesture

    Read more »
  3. Bakr's story: living with ALS in the UAE

    Still walking and talking after 4 years with ALS: we share Bakr's experience of living with a rare disease in the UAE to further his goal of creating awareness and to connect with other ALS patients.

    bakr and wife daad blue sides

    Read more »
  4. Phase 2 study: Ibudilast's effects in progressive MS

    Phase 2 clinical trial shows that ibudilast is linked to a 48% slowing in the progression of brain atrophy compared to placebo for patients with progressive MS.

    red mri brain scan

    Read more »
  5. Vyndaqel (tafamidis): Amyloidosis treatment approved by the FDA

    Vyndaqel (tafamidis) is now approved in the U.S. after study showed increased survivorship rate and reduced hospital time due to heart related problems.

    US flag thumbs up gesture

    Read more »
  6. FDA gives go-ahead for MN166 (ibudilast) to begin phase 2b/3 clinical trials

    Approval for next phase of clinical trials puts ALS patients one step closer to accessing new treatment shown to slow disease progression.

    FDA Ibudilast molecule and pills

    Read more »
  7. Fact Sheet for Healthcare Professionals

    Downloadable fact sheet answering the most common question TheSocialMedwork asked by healthcare providers.

    doctor ok sign

    Read more »
  8. I love someone who is rare

    In recognition of Rare Disease Day, our colleague, Sera, shares her story of her dad's fight with Multiple System Atrophy (MSA). 

    rare patient with heart

    Read more »
  9. Kalydeco (ivacaftor) now approved in Canada for children aged 1-2

    Based on promising results from phase III clinical trials, Health Canada has decided to extend the use of Kalydeco (ivacaftor) to include children aged 1 to 2 years. 

    toddler in park with bubles

    Read more »
  10. Prescriber: TheSocialMedwork, providing access to overseas medicines

    Prescriber

    Read more »
Posts loader